IBM introduces machine learning to diagnose Alzheimer’s
IBM reported on 3/11/2019 that it used machine learning to identify sets of proteins in blood that are predictive of a biomarker in spinal fluid. This new type of blood testing is not only an effective and noninvasive diagnostic technology for early-onset Alzheimer’s, but also the first to use a machine learning approach. Patent data further indicate IBM‘s commitment to using artificial intelligence in the biotech sector.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…